Results 231 to 240 of about 20,173 (272)
Some of the next articles are maybe not open access.
Neuroprotective potency of kynurenic acid against excitotoxicity
NeuroReport, 2000The aim of this study was to determine in vivo which extracellular levels of kynurenic acid (KYNA) are required to control excessive NMDA receptor activation in the rat cortex. As excitotoxicity is coupled to marked ion movements, local depolarisations induced by perfusion of NMDA or quinolinic acid (QUIN) through microdialysis probes were recorded at ...
J, Urenjak, T P, Obrenovitch
openaire +2 more sources
KYNURENIC ACID — I. SPECTROSCOPIC PROPERTIES
Photochemistry and Photobiology, 1979Abstract— The presence of different ground state species in ionic and/or keto s enol equilibrium has been demonstrated by studying NMR, IR and UV spectroscopic properties of kynurenic acid and related quinoline derivatives. The optical and emission properties of kynurenic acid and related compounds are thus very sensitive to pH conditions. Fluorescence
M. P. Pileni, M. Giraud, R. Santus
openaire +1 more source
Developmental changes in brain kynurenic acid concentrations
Developmental Brain Research, 1992The cerebral distribution and regulation of excitatory amino acid levels may play a crucial role in neuronal development. In the present study we examined concentrations of the endogenous excitatory amino acid antagonist kynurenic acid and related substances during development in fetal and neonatal rat brain and fetal non-human primate cerebral cortex.
M F, Beal, K J, Swartz, O, Isacson
openaire +2 more sources
Kynurenic acid actions in brain and periphery
International Congress Series, 2007Abstract. Kynurenic acid (KYNA) is commonly considered a non-competitive NMDA receptor antagonist. It has been recently shown that KYNA also antagonizes the alpha 7 nicotine receptors and reduces glutamate and dopamine release in the rat striatum. Finally, it has been demonstrated that KYNA interacts with GPR35, an orphan receptor negatively coupled ...
MORONI, FLAVIO +3 more
openaire +2 more sources
EXCRETION OF KYNURENIC ACID AND XANTHURENIC ACID DURING INFECTION
Pediatrics, 1971Urinary excretion of diazotizable amines in acute febrile disease was demonstrated 90 years ago. These substances were subsequently identified as metabolites of tryptophan via the kynurenine pathway and the hepatic enzyme tryptophan pyrrolase (TP) was established as a regulator of this pathway.
R C, Shaw, R D, Feigin
openaire +2 more sources
Synthesis of New Substituted Kynurenic Acids
Organic Preparations and Procedures International, 2017Kynurenic acid (4-hydroxyquinoline-2-carboxylic acid) and its derivatives play a crucial role in maintaining normal brain function.1 Several kynurenic acid derivatives containing halo, amino, hydro...
Ajoy K. Banerjee, William J. Vera
openaire +1 more source
Tautomeric polymorphism of the neuroactive inhibitor kynurenic acid
Acta Crystallographica Section C Structural Chemistry, 2019Kynurenic acid (KYN; systematic name: 4-hydroxyquinoline-2-carboxylic acid, C10H7NO3) displays a therapeutic effect in the treatment of some neurological diseases and is used as a broad-spectrum neuroprotective agent. However, it is understudied with respect to its solid-state chemistry and only one crystal form (α-KYN·H2O) has been reported up to now.
Dorota, Pogoda +4 more
openaire +2 more sources
Quinolinic Acid and Kynurenic Acid in the Mammalian Brain
1991Over the last decade, the study of neuroexcitatory amino acids has become one of the most rapidly expanding areas of neuroscientific research. Interest in this class of compounds was precipitated mainly by the realization that metabolites such as glutamate and aspartate are major neurotransmitters in the central nervous system (Fonnum, 1984; Erecinska ...
R, Schwarcz, F, Du
openaire +2 more sources
Production of Quinolinic Acid and Kynurenic Acid by Human Glioma
1991Using biochemical and immunohistochemical techniques, the biosynthesis of the excitotoxin quinolinic acid (QUIN) and the anti-excitotoxin kynurenic acid (KYNA) in the rat brain has been demonstrated to take place preferentially in glial cells (see Schwarcz and Du, this volume, for review). Although a dysfunction of either of these two brain metabolites
Vezzani, A +3 more
openaire +3 more sources
Kynurenic acid antagonists and kynurenine pathway inhibitors
Expert Opinion on Investigational Drugs, 2001The kynurenine pathway accounts for the metabolism of around 80% of non-protein tryptophan metabolism. It includes both an agonist (quinolinic acid) at NMDA receptors and an antagonist (kynurenic acid). Since their discovery, there has been a major development of kynurenic acid analogues as neuroprotectants for the treatment of stroke and ...
openaire +2 more sources